去甲肾上腺素预防腰硬联合麻醉剖宫产低血压的剂量探索研究
该随机双盲剂量探索研究纳入99例择期剖宫产患者,在鞘内注射10 mg布比卡因+5 μg舒芬太尼后立即给予0、0.04、0.05、0.06或0.07 μg/kg/min去甲肾上腺素预防性输注。主要结局为低血压发生率及ED50/ED95,结果显示低血压发生率随剂量增加而降低,ED50、ED80、ED95分别为0.029、0.068、0.105 μg/kg/min,0.07 μg/kg/min可能是最佳预防剂量。
要点
- 去甲肾上腺素预防剖宫产腰麻后低血压的ED50为0.029 μg/kg/min。
- ED80和ED95分别为0.068和0.105 μg/kg/min。
- 0.07 μg/kg/min输注可能为最佳预防剂量,低血压发生率15%。
核心结论
- 去甲肾上腺素预防剖宫产腰麻后低血压的ED50、ED80和ED95分别为0.029、0.068和0.105 μg/kg/min。
- 0.07 μg/kg/min去甲肾上腺素输注可能是预防鞘内注射10 mg布比卡因复合5 μg舒芬太尼后低血压的最佳剂量。
研究设计与样本
- 随机双盲剂量探索研究,在中国嘉兴大学附属妇女儿童医院进行,纳入99例择期剖宫产患者。
- 排除ASA III级及以上、子痫前期或高血压、孕前或妊娠期糖尿病、BMI>35 kg/m²、身高<150 cm或>175 cm及局麻禁忌者。
主要发现
- 低血压发生率在0、0.04、0.05、0.06和0.07 μg/kg/min组分别为70%、47.4%、40%、20%和15%。
- ED50为0.029 μg/kg/min(95%CI 0.008至0.042),ED80为0.068 μg/kg/min(95%CI 0.055至0.099),ED95为0.105 μg/kg/min(95%CI 0.082至0.172)。
- 各组Apgar评分或脐动脉pH相似。
关键数值与推荐
- 预防性输注去甲肾上腺素剂量分别为0、0.04、0.05、0.06、0.07 μg/kg/min,于鞘内注射10 mg布比卡因+5 μg舒芬太尼后立即开始。
- ED50、ED80、ED95采用Probit分析估计。
临床怎么用
- 对于鞘内注射10 mg布比卡因复合5 μg舒芬太尼的剖宫产患者,可考虑0.07 μg/kg/min去甲肾上腺素预防性输注以降低腰麻后低血压发生率。
- 临床决策时应结合患者个体情况,并注意去甲肾上腺素相关不良反应监测。
局限性
- 研究仅纳入特定麻醉方案(10 mg布比卡因+5 μg舒芬太尼)和特定人群,结果外推需谨慎。
- 样本量较小(99例),可能影响结果精确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During caesarean delivery under spinal anaesthesia hypotension may be managed by norepinephrine in preference to phenylephrine due a perception of less bradycardia and fewer reductions in cardiac output. OBJECTIVE: As the optimum prophylactic dose of norepinephrine is unclear, we aimed to investigate its dose-response for preventing postspinal hypotension in caesarean delivery. DESIGN: A randomised, double-blinded, dose-finding study. SETTING: Jiaxing University affiliated Women and Children Hospital, Jiaxing, China. PATIENTS: Ninety-nine patients undergoing elective caesarean delivery from 1 February to 5 August: excluding patients with ASA III or above, preeclampsia or hypertension, pre-existing or gestational diabetes, BMI more than 35 kg m, height less than 150 cm or with more than 175 cm, or with contraindications to local anaesthesia. INTERVENTIONS: Patients received 0, 0.04, 0.05, 0.06 or 0.07 μg kg min preventive norepinephrine infusions immediately after intrathecal injection of 10 mg bupivacaine with 5 μg sufentanil. MAIN OUTCOME MEASURES: The norepinephrine (Median effective dose) or (95% effective dose) ED50 and ED95, which were estimated using Probit analysis to compare haemodynamic changes associated with the different doses. RESULTS: The incidence of hypotension was 70, 47.4, 40, 20 and 15% in the 0, 0.04, 0.05, 0.06 and 0.07 μg kg min groups, respectively. The ED50, ED80 and ED95 values were 0.029 (95% CI 0.008 to 0.042 μg kg min), 0.068 (95% CI 0.055 to 0.099 μg kg min) and 0.105 μg kg min (95% CI 0.082 to 0.172 μg kg min), respectively. Apgar scores or umbilical arterial pH were similar among groups. CONCLUSION: The ED50, ED80 and ED95 were 0.029, 0.068 and 0.105 μg kg min respectively. A 0.07 μg kg min norepinephrine infusion may be optimum for preventing postspinal hypotension after intrathecal injection of 10 mg bupivacaine combined with 5 μg sufentanil. TRIAL REGISTRATION: Chinese Clinical Trial Registry (identifier: ChiCTR-TRC-1800014614).
引用
- Wei C, Qian J, Zhang Y, et al. Norepinephrine for the prevention of spinal-induced hypotension during caesarean delivery under combined spinal-epidural anaesthesia: Randomised, double-blind, dose-finding study. Eur J Anaesthesiol. 2020. PMID: 31977628. doi:10.1097/EJA.0000000000001152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。